Mutations of TGFβR-II and SMAD4 are rare in NSCLC [95], whereas epidermal growth factor receptor (EGFR) and KRAS mutations are frequently found in lung adenocarcinomas [96]. Here, EGFR is linked to lung adenocarcinoma.